|
|
|
* - may be subscription-only |
|
|
- Abpro: Statement on the Departure of Former CEO
Ian Chan More
- Biogen: Initiates Phase 3 Study of Felzartamab for
the Treatment of Late Antibody-Mediated Rejection
(AMR) in Kidney Transplant Patients More
- Cellino and Matricelf: Global Collaboration to Scale
Personalized Spinal Cord Injury Treatments More
- CervoMed: Positive Results From the Extension Phase
of Its Phase 2b Clinical Study of Neflamapimod in
Patients With Dementia With Lewy Bodies More
- Harbour BioMed: Appoints Dr. Ian Y. Liu as Global
Head of Legal More
- Harbour BioMed: Appoints Michael D. Patten as
Chief Strategy Officer More
- Hudson Therapeutics: U.S. Subsidiary of Shaperon
Announces Initiation of Phase 2b Part 2 Clinical Trial
for NuGel More
- Miach Orthopaedics: FDA Approves Expanded Use of
BEAR Implant More
- RoslinCT and Ayrmid Pharma: Their Intent to Enter
Into a Strategic Partnership to Manufacture FDA
Approved Cell Therapy Omisirge (omidubicel-onlv) More
More
- Seaport Therapeutics: Appoints Robert J. Hombach to
Its Board of Directors as Audit Committee Chair More
More
- Seismic Therapeutic: Doses First Cohort in Phase 1
Clinical Trial of S‑1117, a Novel Pan‑IgG Protease
Therapy for Antibody-Mediated Diseases More
|
|
|
|
Section
Sponsor:
|
 |
|
|
|
|
- Agenus: Q4 and Year-End 2024 Results; Strategic
Operational Improvements and Significant Cost
Reductions Enhance Sustainability of Promising
BOT/BAL Program More
- Astria Therapeutics: Fourth Quarter and Full Year
2024 Financial Results and Provides a Corporate
Update More
- Corbus Pharmaceuticals: Q4 and 2024 Financial
Results and Provides a Corporate Update More
- enGene: First Quarter 2025 Financial Results and
Provides Business Update More
- Flagship Pioneering: Unveils Lila Sciences to
Build Superintelligence in Science More
More
More*
- Inozyme Pharma: Full Year 2024 Financial Results
and Announces Strategic Prioritization of ENPP1
Deficiency Pivotal Program and Recent Business
Highlights More
- More on Local Developer of Skin Cancer Drug Being
Acquired for $355M More*
More
- Myomo: Fourth Quarter Financial Results Feature
Record Revenue of $12.1 Million More
- 908 Devices: Receives $1.7M Order From the
Ministry of Health of Ukraine for Its Handheld Mass
Spec Device More
- Rapport Therapeutics: Fourth Quarter and Full Year
2024 Financial Results and Provides Business Update
More
- Q32 Bio: Fourth Quarter 2024 Financial Results and
Provides Corporate Update More
- 2seventy bio: Enters Into Definitive Agreement
to be Acquired by Bristol Myers Squibb More
More
More*
More*
- Xilio Therapeutics: Pipeline and Business Updates
and Fourth Quarter and Full Year 2024 Financial
Results More
|
|
|
|
Section
Sponsor:
|
 |
|
|
|
|
- Boston Drug Testing Startup Wins SXSW Pitch Contest
More*
- Moderna Suffers Setback in Vaccine Patent Battle
With Pfizer More*
- More on Beam Sharing Promising First Clinical
Data on Gene Editing Treatment for a Lung and Liver
Disease More*
More
More
More
- More on Harvard Enterprise Research Campus Landing
First Corporate Partner More*
- Subscribe to LifeSci Startup for Updates on
US Startups More
|
|
|
|
Section
Sponsor:
|
 |
|
|
| SECTION SPONSOR: |
 |
|
|
- Big4Bio:Boston Life Science Company
Directory More
|
NOTE:
EVENTS AND JOBS ARE FROM ALL BIG4BIO REGIONS
|
|
|
|
- OPPORTUNITY: Head of CMC More
- OPPORTUNITY: Chief Product Officer More
- OPPORTUNITY: Chief Medical Officer More
- OPPORTUNITY: Department Chair of Vascular Surgery More
- OPPORTUNITY: Vice President of Enterprise More
- OPPORTUNITY: Head of Operations More
- OPPORTUNITY: Vice President of Clinical Affairs More
- OPPORTUNITY: Laboratory Leader More
- OPPORTUNITY: Senior Manufactuing Engineer More
|
|
|
|
Section
Sponsor:
|
|
|
|
|
